M

Matinas BioPharma Holdings Inc
F:6LJ

Watchlist Manager
Matinas BioPharma Holdings Inc
F:6LJ
Watchlist
Price: 2.69 EUR Market Closed
Market Cap: 674.7m EUR

Net Margin
Matinas BioPharma Holdings Inc

0%
Current
-699%
Average
-6.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
0%
=
Net Income
-18m
/
Revenue
0

Net Margin Across Competitors

No Stocks Found

Matinas BioPharma Holdings Inc
Glance View

Market Cap
674.7m EUR
Industry
Biotechnology

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Bedminster, New Jersey and currently employs 34 full-time employees. The company went IPO on 2014-06-03. The firm is focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology (LNC Platform) to maximize global clinical impact and patient access. The Company’s lead anti-fungal product candidate, MAT2203, is an application of its LNC Platform to a broad spectrum and potent anti-fungal drug called amphotericin B. Its second clinical-stage LNC-based product candidate is MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin, which may be used to treat different types of multidrug-resistant bacteria, including NTM, as well as various multidrug-resistant gram-negative and intracellular bacterial infections. The company also has internal discovery programs ongoing in the formulation and delivery of small oligonucleotides, namely antisense oligonucleotides (ASOs) and silencing or short interfering RNAs (siRNAs).

6LJ Intrinsic Value
Not Available
M
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
0%
=
Net Income
-18m
/
Revenue
0
What is the Net Margin of Matinas BioPharma Holdings Inc?

Based on Matinas BioPharma Holdings Inc's most recent financial statements, the company has Net Margin of 0%.

Back to Top